HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bruce A Mungall Selected Research

Henipavirus Infections

8/2010Characterization of the antiviral and inflammatory responses against Nipah virus in endothelial cells and neurons.
1/2010Off Label Antiviral Therapeutics for Henipaviruses: New Light Through Old Windows.
6/2009Characteristics of Nipah virus and Hendra virus replication in different cell lines and their suitability for antiviral screening.
12/2008Inhibition of Henipavirus infection by RNA interference.
9/2007Vertical transmission and fetal replication of Nipah virus in an experimentally infected cat.
12/2006Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine.
7/2005Inhibition of Henipavirus fusion and infection by heptad-derived peptides of the Nipah virus fusion glycoprotein.
6/2005Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Bruce A Mungall Research Topics

Disease

9Infections
05/2014 - 07/2004
8Henipavirus Infections
08/2010 - 06/2005
5Virus Diseases (Viral Diseases)
11/2009 - 07/2005
4Human Influenza (Influenza)
01/2018 - 11/2002
1Pneumococcal Infections
02/2022
1Whooping Cough (Pertussis)
01/2021
1Pneumonia (Pneumonitis)
01/2018
1Hepatitis B
05/2014
1Hepatitis
05/2014
1Ebola Hemorrhagic Fever
01/2013
1Vasculitis (Vasculitides)
08/2010
1Vesicular Stomatitis
11/2009
1Paramyxoviridae Infections (Parainfluenza)
07/2009
1Malaria
05/2009
1Zoonoses
09/2007

Drug/Important Bio-Agent (IBA)

7VaccinesIBA
02/2022 - 07/2004
5Antiviral Agents (Antivirals)IBA
05/2014 - 06/2009
5Glycoproteins (Glycoprotein)IBA
01/2013 - 07/2005
4Neuraminidase (Sialidase)IBA
07/2009 - 11/2002
2Proteins (Proteins, Gene)FDA Link
02/2022 - 07/2009
2Immunoglobulin G (IgG)IBA
01/2021 - 01/2006
2Influenza Vaccines (Influenza Vaccine)FDA Link
01/2018 - 07/2004
2Immunoglobulins (Immunoglobulin)IBA
01/2013 - 01/2006
2Hemagglutinins (Hemagglutinin)IBA
07/2004 - 11/2002
1Conjugate VaccinesIBA
02/2022
110-valent pneumococcal conjugate vaccineIBA
02/2022
1AlkaloidsIBA
05/2014
1isoquinolineIBA
05/2014
1NucleosidesIBA
05/2014
1EpitopesIBA
01/2013
1C-Type Lectins (C-Type Lectin)IBA
01/2013
1Complement System Proteins (Complement)IBA
01/2013
1CarbohydratesIBA
01/2013
1Polysaccharides (Glycans)IBA
01/2013
1LectinsIBA
01/2013
1ChemokinesIBA
08/2010
1Calmodulin (Calcium-Dependent Activator Protein)IBA
01/2010
1CalciumIBA
01/2010
1Calcium Channels (Calcium Channel)IBA
01/2010
1GliotoxinIBA
11/2009
1Viral HemagglutininsIBA
07/2009
1Ribavirin (Virazole)FDA LinkGeneric
06/2009
1Chloroquine (Aralen)FDA LinkGeneric
05/2009
1Small Interfering RNA (siRNA)IBA
12/2008
1ElementsIBA
09/2007
1Subunit VaccinesIBA
12/2006
1EnzymesIBA
01/2006
1ImmunosorbentsIBA
01/2006
1Peptide Hydrolases (Proteases)FDA Link
07/2005
1Ephrin-B2 (Ephrin B2)IBA
07/2005
1Peptides (Polypeptides)IBA
07/2005
1Virus ReceptorsIBA
06/2005
1Oseltamivir (Tamiflu)FDA Link
07/2004
1Zanamivir (Relenza)FDA Link
07/2004

Therapy/Procedure

1Therapeutics
12/2008